drivetherapeutics.com valuation and analysis

Robots.txt Information
Robot Path Permission
GoogleBot / ✔
BingBot / ✔
BaiduSpider / ✔
YandexBot / ✔ 
User-agent: * Allow: / # Optimization for Google Ads Bot User-agent: AdsBot-Google-Mobile User-agent: AdsBot-Google Disallow: /_api/* Disallow: /_partials* Disallow: /pro-gallery-webapp/v1/galleries/* # Block PetalBot User-agent: PetalBot Disallow: / Sitemap: https://www.drivetherapeutics.com/sitemap.xml # Auto generated, go to SEO Tools > Robots.txt Editor to change
Meta Tags
Title Aptamers to Treat Retinal Disease | Drive Therapeutics |
Description Biotechnology start-up based in RTP, NC. Drive Therapeutics has developed novel aptamer based therapies for wAMD, DME and other retinal diseases that will address efficacy and treatment intervals in these
Keywords Simplify, Your
Server Information
WebSite drivetherapeutics favicondrivetherapeutics.com
Host IP 185.230.63.107
Location -
Related Websites
Site Rank
More to Explore
drivetherapeutics.com Valuation
US$2,183,847
Last updated: 2023-05-17 06:38:10

drivetherapeutics.com has Semrush global rank of 4,846,633. drivetherapeutics.com has an estimated worth of US$ 2,183,847, based on its estimated Ads revenue. drivetherapeutics.com receives approximately 251,983 unique visitors each day. Its web server is located in -, with IP address 185.230.63.107. According to SiteAdvisor, drivetherapeutics.com is safe to visit.

Traffic & Worth Estimates
Purchase/Sale Value US$2,183,847
Daily Ads Revenue US$2,016
Monthly Ads Revenue US$60,476
Yearly Ads Revenue US$725,710
Daily Unique Visitors 16,799
Note: All traffic and earnings values are estimates.
DNS Records
Host Type TTL Data
drivetherapeutics.com. A 3600 IP: 185.230.63.107
drivetherapeutics.com. A 3600 IP: 185.230.63.171
drivetherapeutics.com. A 3600 IP: 185.230.63.186
drivetherapeutics.com. NS 86400 NS Record: ns7.wixdns.net.
drivetherapeutics.com. NS 86400 NS Record: ns6.wixdns.net.
drivetherapeutics.com. MX 3600 MX Record: 5 alt1.aspmx.l.google.com.
drivetherapeutics.com. MX 3600 MX Record: 1 aspmx.l.google.com.
drivetherapeutics.com. MX 3600 MX Record: 10 alt3.aspmx.l.google.com.
drivetherapeutics.com. MX 3600 MX Record: 6 alt2.aspmx.l.google.com.
drivetherapeutics.com. MX 3600 MX Record: 10 alt4.aspmx.l.google.com.
drivetherapeutics.com. MX 3600 MX Record: 15 46prlrrcveemdb3nejcnaldsv2k4brctt5lmcchfp57c62yt43a.mx-verification.google.com.
HtmlToTextCheckTime:2023-05-17 06:38:10
top of page Home Platform Team Pipeline News Blog Contact Get In Touch Jul 27, 2021 1 min Drive Therapeutics awarded a Phase 1 SBIR from the NSF 204 0 2 likes. Post not marked as liked 2 Feb 5, 2021 1 min Drive Receives Funding from NC Biotech Center 89 0 1 like. Post not marked as liked 1 Jul 9, 2020 2 min Welcome Doug Gooding to the Drive Therapeutics Team! 196 0 3 likes. Post not marked as liked 3 Get in Touch Submit Thanks for submitting! Our Innovative Technology The Possibilities Are Endless ​ Retinal diseases, including wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) affect over 2.2 million Americans. The treatment for both retinal diseases is the same and has been revolutionized by the advent of anti-VEGF therapy, which has come to dominate the market. While anti-VEGF therapies improve many patients’ lives, a significantly large portion of patients do not respond or fully benefit from treatment (~50% in the case of DME and 25-75%, in the case of
HTTP Headers
HTTP/1.1 301 Moved Permanently
Date: Thu, 10 Mar 2022 09:26:31 GMT
Content-Length: 0
Connection: keep-alive
location: https://www.drivetherapeutics.com/
strict-transport-security: max-age=3600
x-wix-request-id: 1646904391.3473683571609820559
Age: 0
Server-Timing: cache;desc=miss, varnish;desc=miss, dc;desc=84
X-Seen-By: yKskFaTI/RmB0yGOaMOo6Q==,sHU62EDOGnH2FBkJkG/Wx8EeXWsWdHrhlvbxtlynkVg/3AO33ORdxyJYf9RAAk9b,m0j2EEknGIVUW/liY8BLLhNTJsN9qAg6er86JlpS9OLJftmKrOReD3ukbbas4YDo,2d58ifebGbosy5xc+FRalpNh0Z5Lckt/uy+PUtRTWIb1MnHq8UPzMnqyTTNhsdWduPqvO2K7rn5K4sGawbYFcg==,2UNV7KOq4oGjA5+PKsX47MrVZEzBMcoq97TK4HZFAZG8ZDY613cHYLbuhNMgAom1,VRYHOKNtMYMbjSnTMvCGgwR8+PtNm8Xd7sMXSdPGjE7wcXiCJjelMQdweukbvEnQ,sqmudy1rWy5CXemzdhzS/HEMQvHowsdlxJ5IjwvVEL2TzRA6xkSHdTdM1EufzDIPWIHlCalF7YnfvOr2cMPpyw==,WHOG0+z0OllpcvLoF6CtMNBNWbA/6oQoOIw5s+aJZfI/TNwEL7/Uxb8RK5lVDZx42cQ05vDOdQk69C2nYmpoTg==
Cache-Control: no-cache
X-Content-Type-Options: nosniff

HTTP/2 200 
date: Thu, 10 Mar 2022 09:26:31 GMT
content-type: text/html; charset=UTF-8
link: ; rel=preconnect; crossorigin;,; rel=preconnect;,; rel=preconnect; crossorigin;,; rel=preconnect; crossorigin;,; rel=preconnect;,; rel=preconnect; crossorigin;,
x-wix-request-id: 1646904391.58652261612526863
content-language: en
strict-transport-security: max-age=3600
age: 0
x-seen-by: GXNXSWFXisshliUcwO20NXdyD4zpCpFzpCPkLds0yMcVebSSicDNkU5XWs3CW9fL,qquldgcFrj2n046g4RNSVBKUaXHrucSLmP/C0nqrtU9YgeUJqUXtid+86vZww+nL,2d58ifebGbosy5xc+FRaluNDT+CRLjFAmS2GzVnHdC9ZTqeI15aPAZb/RFWYLbxJ3QpI/ucnHvfrUjeESIoVemY+Vb5mZAuxvnp5+jSyCxM=,2UNV7KOq4oGjA5+PKsX47Dup3Er3OeJdBpGMGRuuaaaa46R9xNIlpQ4eUPYpBuqs,VRYHOKNtMYMbjSnTMvCGgwR8+PtNm8Xd7sMXSdPGjE7wcXiCJjelMQdweukbvEnQ,l7Ey5khejq81S7sxGe5Nk/78+yMjRC2h8GQNrS0i4/FXz5t7NzGxeu2CXkk1aB7ZGlsroP2XR0N+rjgJK/PU9A==,4EmzKGKKpFffqfFwZRPY8U3OqOdz9Eqo+OM/x8xv02+sFET13JkWiCWyIXlCNbDbL6N2ln7JpxtqCGQ7leK5kA==,l7Ey5khejq81S7sxGe5Nk/78+yMjRC2h8GQNrS0i4/FXz5t7NzGxeu2CXkk1aB7ZGlsroP2XR0N+rjgJK/PU9A==,l7Ey5khejq81S7sxGe5Nk8dSVZfudpCjfHFE0V01n+iTzRA6xkSHdTdM1EufzDIPWIHlCalF7YnfvOr2cMPpyw==,LoUK8/saGAmOxZWtpubo2hCTZIovVLWxYnpvwA85+h58KimidSOt9R7ch4mdEOoXU/C/esKnCuS+FO+4bPehcA==,l7Ey5khejq81S7sxGe5Nk8dSVZfudpCjfHFE0V01n+iTzRA6xkSHdTdM1EufzDIPWIHlCalF7YnfvOr2cMPpyw==,l7Ey5khejq81S7sxGe5NkyE6yVy+QtzURdr94qfraLZXz5t7NzGxeu2CXkk1aB7ZGlsroP2XR0N+rjgJK/PU9A==,/a5ccLSK1HEmwPNg/x6OukIT+c5HqyHveWvXmN7dchp4bL5g0j8IGqFN2Qgvdc33slQQA44kRaQnD0pyVy4ezfXsz5aD6xiSLK9evl88Rc0=
cache-control: no-cache
vary: Accept-Encoding
accept-ranges: bytes
set-cookie: ssr-caching=cache#desc=miss#varnish=miss#dc#desc=eun1_g; Max-Age=20; Expires=Thu, 10 Mar 2022 09:26:51 GMT
server-timing: cache;desc=miss, varnish;desc=miss, dc;desc=eun1_g
x-content-type-options: nosniff
server: Pepyaka/1.19.10
via: 1.1 google
alt-svc: h3=":443"; ma=2592000,h3-29=":443"; ma=2592000,h3-Q050=":443"; ma=2592000,h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000,quic=":443"; ma=2592000; v="46,43"
drivetherapeutics.com Whois Information
Domain Name: DRIVETHERAPEUTICS.COM
Registry Domain ID: 2450336913_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.godaddy.com
Registrar URL: http://www.godaddy.com
Updated Date: 2021-11-02T13:06:39Z
Creation Date: 2019-11-01T13:57:45Z
Registry Expiry Date: 2022-11-01T13:57:45Z
Registrar: GoDaddy.com, LLC
Registrar IANA ID: 146
Registrar Abuse Contact Email: abuse@godaddy.com
Registrar Abuse Contact Phone: 480-624-2505
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS6.WIXDNS.NET
Name Server: NS7.WIXDNS.NET
DNSSEC: unsigned
>>> Last update of whois database: 2022-03-10T10:11:17Z <<<

Copyright © 2022 WebZZ.US 0.0262